September 25, 2024 07:00 AM EDTUpdated September 27, 11:08 PM
R&D
Pharma

2sev­en­ty bio, Bris­tol My­ers stop late-stage Abec­ma study in mul­ti­ple myelo­ma due to re­cruit­ment chal­lenges

Katherine Lewin

News Reporter

2sev­en­ty bio and its part­ner Bris­tol My­ers Squibb said Wednes­day that they are dis­con­tin­u­ing en­roll­ment in the Phase 3 Kar­M­Ma-9 study in­ves­ti­gat­ing Abec­ma in pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times